JMKX007129: A Next‑Generation AR‑NTD Inhibitor for Overcoming Resistance in mCRPC

JMKX007129 is a new small‑molecule drug that targets the N‑terminal domain (NTD) of the androgen receptor (AR) in prostate cancer. It is designed to overcome resistance seen with current AR‑ligand binding domain (LBD) inhibitors, which often stop working in castration‑resistant prostate cancer (CRPC) when AR develops mutations or produces splice variants like AR‑V7. JMKX007129 builds on an earlier class of drugs called anitens, improving their potency, selectivity, and safety.

In lab studies, JMKX007129 binds both full‑length AR and AR‑V7, blocking their activity in LNCaP and 22RV1 cells. The compound suppresses AR‑ and AR‑V7‑driven gene expression and strongly stops the growth of AR‑positive prostate cancer cells. It is about 20‑fold more active in these cells than in AR‑negative ones, suggesting it hits AR specifically rather than killing cells in a nonspecific way. The drug works in AR‑inhibitor‑sensitive models such as LNCaP and in resistant models like VCaP and 22RV1, which carry AR‑LBD mutations or express AR‑V7.

Studies in animal models show that JMKX007129 has favorable pharmacokinetics and can reach levels that shrink tumors in vivo while remaining well tolerated. In 22RV1 cells, it also combines well with existing AR inhibitors or degraders, producing a stronger anti‑growth effect than any one drug alone. This synergy suggests that pairing AR‑NTD inhibition with LBD‑targeting agents may be a better strategy for resistant disease.

Overall, JMKX007129 represents a more refined attempt to make AR‑NTD inhibition work in patients. Earlier aniten‑based drugs showed the idea was possible but failed in the clinic because they were not selective or potent enough. JMKX007129 aims to fix those problems and is now moving into IND‑enabling work, bringing the field closer to testing whether targeting the AR N‑terminal domain can truly help men with advanced, treatment‑resistant prostate cancer who have run out of effective options.

Source.